Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Kuhnl A. et al, (2019), BLOOD, 134
Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common
Booth S. et al, (2019), BLOOD, 134
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA. et al, (2019), Hematol Oncol, 37, 352 - 359
Meaningfulness of HM-PRO scores: translating the science of PROs into practice
Goswami P. et al, (2019), QUALITY OF LIFE RESEARCH, 28, S84 - S85
Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
Djebbari F. et al, (2019), Br J Haematol, 186, e191 - e195
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.
Kesavan M. et al, (2019), Curr Hematol Malig Rep, 14, 207 - 218
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.
Scarisbrick JJ. et al, (2019), Br J Dermatol, 181, 350 - 357
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A. et al, (2019), Lancet Oncol, 20, 649 - 662
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
Goswami P. et al, (2019), J Comp Eff Res, 8, 523 - 533
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA. et al, (2019), British journal of haematology
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly Diffuse large B cell lymphoma (DLBCL) patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA. et al, (2019), Journal of internal medicine
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA. et al, (2019), Haematologica, 104, e68 - e71
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK. et al, (2019), Br J Haematol, 184, 547 - 557
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA. et al, (2019), Cancer, 125, 99 - 108